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Abstract
Background: The mechanistic target of rapamycin complex 1 (mTORC1) is a well-conserved serine/threonine protein
kinase that controls autophagy as well as many other processes such as protein synthesis, cell growth, and metabolism.
The activity of mTORC1 is stringently and negatively controlled by the tuberous sclerosis proteins 1 and 2 complex
(TSC1/2).
Results: In contrast to the previous studies using Tsc1 knockout mouse embryonic fibroblasts (MEF) cells, we
demonstrated evidence that TSC1 deficient macrophages exhibited enhanced basal and mycobacterial infection-induced
autophagy via AMPKα-dependent phosphorylation of ULK1 (Ser555). These effects were concomitant with constitutive
activation of mTORC1 and can be reversed by addition of amino acids or rapamycin, and by the knockdown of the
regulatory-associated protein of mTOR, Raptor. In addition, increased autophagy in TSC1 deficient macrophages
resulted in suppression of inflammation during mycobacterial infection, which was reversed upon amino acid
treatment of the TSC1 deficient macrophages. We further demonstrated that TSC1 conditional knockout mice
infected with Mycobacterium tuberculosis, the causative agent of tuberculosis, resulted in less bacterial burden
and a comparable level of inflammation when compared to wild type mice.
Conclusions: Our data revealed that sustained activation of mTORC1 due to defects in TSC1 promotes
AMPKα-dependent autophagic flux to maintain cellular homeostasis.
Keywords: AMP-activated protein kinase (AMPK), Autophagy, Mechanistic target of rapamycin (mTOR),
Mycobacterium tuberculosis, Macrophages, Tuberous sclerosis 1 (TSC1)
Background
Autophagy is a fundamental and phylogenetically con-
served self-degradation process that is characterized by the
formation of double-layered vesicles (autophagosomes)
around intracellular cargo for lysosomal delivery and pro-
teolytic degradation [1, 2]. Autophagy is not only involved
in cellular processes like nutrient regeneration and protein
and organelle degradation, but also in clearance of intra-
cellular pathogens, such as M. tuberculosis [3, 4]. Recent
studies suggest that induction of autophagy in macro-
phages is an effective mechanism to enhance intracellular
killing of M. tuberculosis, and that the ability of the patho-
gen to inhibit this process is of paramount importance for
its survival [5, 6]. Autophagy is highly inducible via starva-
tion, rapamycin, infection (virus, intracellular bacteria) and
other cellular and environmental cues [2, 6]. The autopha-
gosomal lipidated microtubule-associated protein 1
light chain 3 (LC3B-II) and the autophagy substrate
sequestosome p62/SQSTM1 are often used to monitor
autophagy [7, 8].
The best characterized regulator of autophagy is
mTOR complex 1 (mTORC1). The rapamycin-sensitive
mTORC1 kinase is composed of mTOR, regulatory-
associated protein of mTOR (Raptor), mammalian lethal
with SEC13 protein 8 (MLST8), the 40-kDa proline-rich
Akt substrate (PRAS40), and DEP domain-containing
mTOR-interacting protein (DEPTOR) [9]. Activation of
mTORC1 depends on on the Ras-related GTPases (Rags)
and Ras homolog enriched in brain (Rheb) GTPase and
requires signals from amino acids, glucose, oxygen, energy
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(ATP), and growth factors (including cytokines and hor-
mones such as insulin) [10].
mTORC1 positively regulates cell growth and prolifera-
tion by promoting many anabolic processes, including bio-
synthesis of proteins, lipids and organelles, and by limiting
catabolic processes such as autophagy [11]. mTORC1 pro-
motes protein synthesis by phosphorylating the eukaryotic
initiation factor 4E (eIF4E)-binding protein 1 (4E-BP1) and
the p70 ribosomal S6 kinase 1 (S6K1) [12, 13]. The phos-
phorylation of 4E-BP1 inhibits its binding to eIF4E, enab-
ling eIF4E to promote translation [14]. The stimulation of
S6K1 activity by mTORC1 leads to increases in mRNA
biogenesis, translation and elongation, and the translation
of ribosomal proteins through regulation of the activity of
many proteins such as ribosomal protein S6 [15]. The
mTORC1 kinase negatively regulates autophagy by inhibit-
ing the activity of the UNC-51-like kinase 1 (ULK1, a yeast
Atg1 homolog) through direct phosphorylation. mTORC1
activity depends on diverse positive signals such as high en-
ergy levels, normoxia, amino acids, and growth factors, all
of which lead to the inhibition of autophagy [16]. Con-
versely, mTORC1 is inhibited when amino acids are scarce
and growth factor signalling is reduced, and/or ATP con-
centrations fall, which results in activation of autophagy
[17]. In addition, autophagy is regulated by AMP-activated
protein kinase (AMPKα) that is widely recognized as a
ubiquitous sensor of cellular energy status and regu-
lates cellular metabolism to maintain energy homeosta-
sis [18, 19]. Unlike the dependence of mTORC1 on
various signals, AMPKα is activated only under low energy
conditions. Under low nutrient conditions, AMPKα pro-
motes autophagy by directly activating ULK1 through
phosphorylation of Ser317, Ser555, and Ser777 [16, 20].
Under nutrient sufficiency, the active mTORC1 suppresses
autophagy by phosphorylating ULK1 at Ser757 and affect-
ing interaction between ULK1 and AMPKα [20, 21]. This
coordinated phosphorylation is essential for ULK1 in au-
tophagy induction.
One of the most important sensors involved in the regu-
lation of mTORC1 activity is the tuberous sclerosis com-
plex (TSC), which is a heterodimer comprised of TSC1
(also known as hamartin) and TSC2 (also known as
tuberin) [11]. TSC1/2 works as a GTPase-activating pro-
tein (GAP) for Rheb. The active, GTP-bound form of
Rheb directly interacts with mTORC1 to stimulate its ac-
tivity [22, 23]. TSC1 is known to stabilize TSC2 by form-
ing a complex with TSC2 [24, 25] and the genetic data
strongly implicate the complex between TSC1 and TSC2
as the functional unit for these tumour suppressors [24].
Based on the current knowledge of autophagy regula-
tion by mTORC1 [26], our initial hypothesis was that
sustained activation of mTOR impairs autophagy in
TSC1fl/fl LysM-Cre+ mice and thus, TSC1fl/fl LysM-Cre+
mice infected with an intracellular human pathogen,
Mycobacterium tuerculosis, would have a significant bac-
terial burdens and would succumb to M. tuberculosis
infection. To our surprise, the TSC1fl/fl LysM-Cre+ mice
infected with M. tuberculosis showed fewer bacteria in
both spleens and lungs at the peak of infection. Further
in vivo and in vitro analysis reveals that the unexpected
autophagy dysfunction associated with loss of TSC1 in
macrophages. Our results demonstrates that the com-
plex interplay among mTORC1, AMPKα, and ULK1,
and further highlights the importance of autophagy to sup-
port the cellular homeostasis during host-mycobacteria
interactions.
Results
Sustained activation of mTORC1 via loss of TSC1 led to
enhanced accumulation of autophagic markers
Previous studies demonstrated that TSC1 deficient bone
marrow derived macrophages (BMMϕ) constitutively acti-
vated mTORC1 [27]. To determine how TSC1 deficiency
affects autophagy, TSC1f/f LysM-Cre+ mice and TSC1f/
f-ERCre+ mice were used in in vivo and in vitro studies re-
spectively. Since LysMcre mice allow for both specific and
highly efficient Cre–mediated deletion of loxP–flanked tar-
get genes in myeloid cells [28] and M. tuberculosis resides
in macrophages during lung infection, we used TSC1f/
fLysM-Cre+ mice for in vivo studies. For in vitro studies,
we used tamoxifen-dependent Cre recombinases, so-called
CreER recombinases, to generate time- and tissue-specific
mouse mutants [29]. TSC1f/f-ERCre+ BMMϕ were in vitro
differentiated for 3 days [27], at which time BMMϕ size
was similar to controls. Here TSC1 was not detected in
both tamoxifen-treated BMMϕ from TSC1f/f-ERCre+ mice
(Fig. 1a) and peritoneal macrophages from TSC1f/f LysM-
Cre+ mice (Fig. 1b). TSC2 was also diminished in both
macrophages, which indicates that TSC1 stabilizes TSC2
in macrophages and other cell types [30].
As compared with macrophages from wild type control
mice, BMMϕ from TSC1 KO demonstrated increased
mTORC1 activation as shown by elevated phosphoryl-
ation of the mTORC1 downstream target S6 protein
(Fig. 1c). Surprisingly, higher levels of LC3B-II were ob-
served in TSC1 KO macrophages compared to WT coun-
terparts, which is in contrast to the current knowledge
that mTORC1 activation by TSC1/2 loss inhibits au-
tophagy [31, 32]. A reduction in LC3B-II was observed
in TSC1 and TSC2 KO mouse embryonic fibroblasts
(MEFs) [33–35]. However, similar to the MEFs, TSC1
KO macrophages had increased levels of the autophagy
substrate p62 (Fig. 1c).
To evaluate autophagic flux in TSC1 KO macrophages,
both TSC1 WT and KO BMMϕ cells were treated with
bafilomycin A1, an inhibitor of autophagic degradation
that prevents fusion between autophagosomes and lyso-
somes (Fig. 1e, f ). Enchanced LC3B and p62 protein levels
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indicates presence of autophagic flux while no change in-
dicates inhibition of autophagic degradation. As shown in
Fig. 1e and f, both LC3B and p62 proteins substantially
accumulated after bafilomycin A1 treatment, indicating
that there is ongoing autophagic flux in the TSC1 KO
macrophages. In addition, the ratio of LC3-II of bafilomy-
cin treated and untreated macrophages (BafA1 treated/
untreated) indicated that, TSC1 KO macrophages had a
similar level of autophagic flux compared with wild type
control (p = 0.7, data not shown). This result again con-
firms that mTORC1 activity did not affect the LC3-II
transit through the autophagy pathway. Taken together,
the the accumulation of autophagic markers and autopha-
gic activity in the TSC1 KO macrophages suggest that the
autophagy regulation in response to reduced TSC1 func-
tion significantly differs among various cell types.
Suppression of mTORC1 activation in TSC1 KO
macrophages resulted in reduced autophagic activity
To evaluate if and how mTOR activity affects autophagy
in TSC1 deficient cells in the presence of an mTOR
inhibitor, TSC1 KO BMMϕ were treated with rapamycin
(Rapa). Phosphorylation of S6 was inhibited upon rapamy-
cin treatment in TSC1 KO BMMϕ and WT BMMϕ,
which indicates that rapamycin suppresses constitutively
active mTORC1 (Fig. 2a). However, TSC1 KO BMMϕ
treated with various concentrations of rapamycin greatly
reduced LC3B protein levels while the opposite was true
for WT BMMϕ. Interestingly, p62 protein levels were de-
creased in both TSC1 WT and KO BMMϕ after 10 or
100 ng/ml rapamycin treatment (Fig. 2a). Similarly, two
inhibitors of the Class III PI3K required for induction of
autophagy, 3-methyladenine (3-MA) and wortmannin,
greatly reduced LC3B protein levels in TSC1 KO BMMϕ
while bafilomycin A1 treatment demonstrated the accu-
mulation of LC3B-II, again confirming the presence of au-
tophagic flux (Fig. 2b).
To directly examine the regulation of the autophago-
some formation by mTORC1, we used a microscopy-based
assay that quantified green fluorescent protein (GFP)-LC3
puncta formation in the absence and presence of rapamy-
cin. LC3 was the first protein shown to specifically label
autophagosomal membranes in mammalian cells, and sub-
sequently EGFP-LC3 has become one of the most widely
utilized reporters of autophagy [36]. Compared with the
control, TSC1 KO BMMϕ showed higher numbers of
puncta formation (Fig. 2c and d) without rapamycin treat-
ment. However, TSC1 KO BMMϕ treated with rapamycin
displayed a greatly reduced number of puncta while the
same treatment increased the number of puncta in WT
BMMϕ (Fig. 2c and d).
To further confirm this finding with genetic evi-
dence, we generated a knockdown of RAPTOR, an es-
sential component of mTORC1 complex [37], in TSC1
KO BMMϕ using shRNA. The knockdown of RAP-
TOR (TSC1 KO/RAPTOR KD) dramatically reduced
LC3B protein and p-S6 levels in these cells (Fig. 2e).
Taken together, the finding that the reduced activation
of mTORC1 in TSC1 KO macrophages led to reduced
autophagy rather than further increased autophagy,
suggests that strong autophagy induction in the TSC1
KO macrophages may be used to degrade and recycle
the cytoplasmic components and thereby to maintain
the cellular homeostasis.
Fig. 1 Loss of TSC1 led to sustained activation of the mTORC1 and
to increased auto-phagosome formation. Representative Western
blot of TSC1 and TSC2 in bone marrow macrophages from TSC1f/f-
ERCre+ mice (a) and in the resident peritoneal macrophages of
TSC1fl/fl LysM-Cre+ mice (b) did not detect the TSC1 and TSC2 proteins.
Isolated cells from mice were grown in 15 % L929 conditional medium
for 4 days. 4-Hydroxytamoxifen at 2.5 mM was added into L929
conditioned culture medium for 2–3 days before use and the protein
lysates were prepared. c Immunoblot showed significantly increased
basal p-S6, LC3B-II (arrow), and p62 proteins in macrophages isolated
from TSC1 KO mice. d Densitometric quantification of LC3-II (n = 3)
band intensities quantified by ImageJ was normalized to total Actin.
e TSC1 WT and KO BMMϕ were treated with 100 nM bafilomycin A1
for 3 h to measure autophagic flux. f Densitometric quantification of
LC3-II (n = 3) was normalized to total Actin. The experiments were
repeated three times. The arrow indicates LC3B-II. BafA1: bafilomycin A1.
*, p <0.05, **, p< 0.01, ***, p< 0.001
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Mycobacterial infection increased autophagy in TSC1
KO BMMϕ
To examine how constitutively activated mTOR may affect
autophagy during mycobacterial infection, we examined if
activated mTORC1 phosphorylates its downstream sub-
strates in infected TSC1 KO BMMϕ. Uninfected TSC1 KO
macrophages showed an increase in phosphorylation of
p70S6K and ULK1 at the mTORC1-dependent inactivating
site S757 (Fig. 3a) compared with WT macrophages, as ex-
pected. Infection of the TSC1 KO macrophages with M.
tuberculosis strain H37Rv further increased the phosphor-
ylation of p70S6K and the accumulation of LC3B-II and
p62 (Fig. 3a, b, and c). Similar results were observed during
Bacillus Calmette–Guérin (BCG) infection (Fig. 3d, e,
and f ). Phosphorylation of S6, the target substrate of
p70S6K, was also substantially increased with mycobac-
terial infections in both TSC1 KO and WT BMMϕ
(Fig. 3).
To investigate whether mTOR inhibitor, rapamycin,
could alter bacterial-induced autophagy, we treated
both TSC1 WT and KO BMMϕ with rapamycin 1 h
prior to bacterial infection with TB (Fig. 3b and c) and
BCG (Fig. 3d). Surprisingly, rapamycin reduced LC3B
and p62 proteins in TSC1 KO BMMϕ, but increased
them in WT BMMϕ, when compared to their respect-
ive no-rapamycin controls. To examine infection indu-
cible autophagic flux, BMMϕ from TSC1 WT and KO
were infected with BCG with or without bafilomycin
Fig. 2 Autophagy was increased upon inhibition of the mTOR-dependent autphagic pathway in wild type macrophages as expected, but not in
TSC1 KO macrophages. a BMMϕ were treated with the mTOR inhibitor, rapamycin at 0, 10, 100 ng/ml for 24 h, and then lysed for Western blot
analysis. b TSC1 KO BMMϕ were treated with autophagy inhibitors, 5 mM of 3-methyladenine, 1 μM of wortmannin, and 100 μM of bafilomycin
A1 for 2 h. c Autophagic puncta were visulized using immunofluorescent microscopy (1,000X magnification). TSC1 WT and KO BMMϕ were grown
in chamber slides and treated with rapamycin at 20 ng/ml overnight. d The number of puncta was counted in at least 20 cells for each group
under the fluorescent microscope and average number of puncta per cells was calculated. e TSC1 KO BMMϕ were transfected with shLUC (control) or
shRAPTOR lentivirus and selected in the presence of puromycin at 2 μg/ml for 4 days and Western blot analysis was performed with indicated
antibodies including p-AMPKα (T172). All the experiments were repeated at least three times. ImageJ was used to quantify band intensities
and the ratio of LC3B-II/Actin (loading control) is shown. The arrow indicates LC3B-II. Rapa, rapamycin; Un, uninfected; WT, Wild type; KO,
knockout; ShLUC, shRNA control; ShRAPT, ShRAPTOR; 3-MA, 3-methyladenine; Wort, wortmannin; BafA1, bafilomycin A1; **, p < 0.01, ****, p < 0.0001
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A1 (Fig. 3e and f ). Bafilomycin A1 treatment signifi-
cantly increased LC3B and p62 protein accumulation in
the infected TSC1 KO BMMϕ. The findings of the
further enhanced induced-autophagy and concomitant
mTORC1 activation during mycobacterial infection as
well as decreased LC3B-II levels upon rapamycin addition
in the TSC1 KO macrophages suggest that an undiscov-
ered mechanism might regulate autophagy when mTOR
is constitutively activated.
Increased p-AMPKα contributed to enhanced autophagy
in TSC1 KO BMMϕ
Based on the ex vivo studies, we hypothesized that sus-
tainably active mTOR may deplete energy or amino
acids in TSC1 KO BMMϕ, which in turn would induce
autophagy by other autophagy initiation pathways to
overcome starvation. AMPK, activated during low nutri-
ent conditions, directly phosphorylates ULK1 at multiple
sites including Ser317, Ser555, and Ser777 (17,18). Con-
versely, mTOR, which is a regulator of cell growth and
is an inhibitor of autophagy, phosphorylates ULK1 at
Ser757 and disrupts the interaction between ULK1 and
AMPK (17). It is known that autophagy induced by en-
ergetic stress requires AMPK, which directly activates
ULK1 through phosphorylation at Ser555 [2, 33, 38]. To
explore the underlying mechanisms by which constitu-
tively active mTOR induces autophagy, cell lysates from
TSC1 WTand TSC1 KO BMMϕ (Fig. 4a) and from TSC1
KO peritoneal macrophages (Fig. 4b) were examined for
p-AMPKα, p-ULK1 (Ser555), Beclin1, and LC3B protein
levels. Activated ULK1 (Ser555) induces autophagy by
phosphorylating Beclin-1 following amino acid starvation
[20, 39]. Indeed, phosphorylated AMPKα, ULK1 (Ser555),
and Beclin1 protein levels were higher in TSC1 KO
BMMϕ than WT BMMϕ before or after BCG infection
(Fig. 4a, b). TSC1 KO macrophages showed an increase in
ULK1 phosphorylation at the mTORC1-dependent inacti-
vating site S757 (Fig. 3a) as expected. AMP concentration
determined by LC-MS analysis was significantly higher in
TSC1 KO BMMϕ than WT BMMϕ (Fig. 4c). Together,
these data support that sustainably active mTOR causes
energy depletion in TSC1 KO BMMϕ, which in turn in-
creases p-AMPKα and subsequently activates ULK1
(Ser555) to initiate autophagy.
To confirm that LC3B up-regulation in TSC1 KO
BMMϕ was AMPK dependent, compound C (a pharma-
cological AMPK inhibitor) [40], was used to treat TSC1
KO BMMϕ for 1.5 h. As showed in Fig. 4d, compound
Fig. 3 Mycobacterial infection further increased autophagy in TSC1 KO BMMϕ. a Tsc1 KO macrophages have mTORC1-dependent inhibition of
ULK1 at S757. BMMϕ cells from either TSC1 WT or KO BMMϕ were left uninfected or infected with M. tuberculosis strain H37Rv (TB) (a, b, c) or
BCG (d, e, f) at a MOI of 10 for 24 h and lysed for immunoblotting analysis with the indicated antibodies. TSC1 WT and KO BMMϕ were treated
with 100 ng/ml rapamycin (b, d) or with 100 nM bafilomycin A1 (e, f) for 3 h and then lysed for Western blot analysis. c, f Densitometric quantification
of LC3-II (n = 3) was normalized to total Actin in c and e. The arrow indicates LC3B-II. These experiments were repeated three times. BafA1, bafilomycin
A1; BCG, Bacillus Calmette-Guérin; Rapa, rapamycin; TB, M. tuberculosis strain H37Rv, WT, Wild type; KO, knockout; UN, uninfected. *, p < 0.05; **, p <0.01
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C reduced both p-AMPKα level and LC3B protein,
which indicates that AMPK activity regulates autophagy
induction in TSC1 KO BMMϕ cells. Furthermore, rapa-
mycin inhibited the elevated p-AMPKα and reduced
LC3B protein level in KO BMMϕ (Fig. 4e). We tested if
the TSC1 defect associated phenotypes can be reversed
by addition of amino acids or glucose. The addition of
amino acids (Fig. 4f ) into TSC1 KO BMMϕ medium re-
duced both LC3B and p-AMPKα expression levels and
activated mTOR, indicating that sustainably activated
Fig. 4 Increased p-AMPKα contributed to enhanced autophagy in TSC1 KO BMMϕ. TSC1 WT and KO peritoneal macrophages (a) or BMMϕ (b)
were left uninfected or infected with BCG at a MOI of 10 for 24 h and Western blot analysis was performed against the indicated antibodies.
c Quantification of AMP level was performed by LC-MC analysis in TSC1 WT and KO BMMϕ. d Compound C was added into TSC1 KO BMMϕ at
the concentration of 0, 2.5, or 25 μM for 2 h. Cells were subjected to Western blot analysis. e TSC1 KO BMMϕ were treated with rapamycin at 0.1,
10, 100 ng/ml overnight. f Amino acids were added to TSC1 KO BMMϕ for 0, 30, 60 and 120 min. g, h, and i TSC1 KO BMMϕ were left uninfected
or infected with BCG or BCG plus amino acids for 4 h and then lysed with Trizol reagent for qRT-PCR. IL-1β (g), IL-1α (h), and TNFα (i) mRNA levels
in TSC1 KO BMMϕ are shown. Each experiment was repeated at least twice. Densitometric quantification of LC3-II (n = 3) was normalized to total
Actin. The arrow indicates LC3B-II. AA, amino acids; BCG, Bacillus Calmette-Guérin; Comp C, compound C; KO, knockout; Rapa, rapamycin; WT, Wild
type. *, p < 0.05; **, p < 0.01
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mTOR leads to the depletion of amino acids in TSC1
KO BMMϕ. Glucose supplementation did not change
the LC3B level (data not shown).
Dual roles of autophagy in controlling bacterial burden
and suppressing inflammation with features of a Th17
response including neutrophilic infiltration, tissue necro-
sis, and organ damage, have been previously reported
[41]. As such, we were interested in evaluating the in-
flammatory cytokine levels in KO BMMϕ. Total RNA
was isolated from TSC1 KO BMMϕ left uninfected or
infected with BCG with or without amino acids. BCG in-
fected TSC1 KO BMMϕ supplemented with amino acids
displayed increased IL-1α and β mRNA transcripts com-
pared to the cells infected with BCG without amino acid
supplementation (Fig. 4g and h). TNFα mRNA levels were
not affected in the same infected cells (Fig. 4i). These re-
sults suggested that amino acid depletion caused by con-
stitutive activation of mTORC1 activates p-AMPKα and
p-ULK1 (Ser555) to promote autophagy in order to keep
homeostasis in TSC1 KO BMMϕ.
TSC1 KO mice infected with M. tuberculosis H37Rv
showed reduced bacterial burden
Host cells utilize autophagy pathways in their defense
against pathogens. Autophagy limits mycobacterial replica-
tion by targeting phagosomes containing bacteria for fusion
with lysosomes [41, 42]. We further investigated how mice
with basally enhanced autophagy due to TSC1 deficiency in
macrophages survive M. tuberculosis H37Rv infection using
TSC1f/f LysM-Cre+ or littermate control mice. Statistically
significant reduction of bacterial burden was observed in
both lungs (Fig. 5a) and spleens (Fig. 5b) from TSC1f/f
LysM-Cre+ mice 3 weeks post-infection compared to WT
mice, suggesting that greater autophagy induction in
TSC1 deficient macrophages may cause killing of infecting
bacilli. However, there was no statistical difference in lung
and spleen CFUs between TSC1f/f LysM-Cre+ and TSC1f/f
LysM-Cre- mice at 5 weeks post-infection.
Luminex data showed that there was no significant dif-
ference in IL-1α and β secretions in lung homogenates
between TSC1 WT and KO mice; there was also a com-
parable level of proinflammatory cytokines such as IFNγ,
IL-6, IL10, IL12p40, and TNFα in lung homogenates
(Fig. 5c). Major histocompatibility complex II (MHCII)
expression in spleen macrophages was higher in TSC1f/f
LysM-Cre+ than TSC1f/f LysM-Cre- mice at 3 weeks
after M. tuberculosis H37Rv infection (Fig. 5d), which is
consistent with other reports [43–47] and further sup-
ports our finding that there is ongoing autophagy in
TSC1 KO macrophages. Together, TSC1f/f LysM-Cre+
mice were able to temporarily contain M. tuberculosis
H37Rv infection at the time of recruitment of M. tuber-
culosis specific CD4+ T cells to the site of infection, pos-
sibly due to enhanced autophagy.
Discussion
The inhibitory function of mTORC1 in autophagy is well
established [31, 48] as mTORC1 activity reflects cellular
nutritional status [49]. Our initial hypothesis was that con-
stitutive mTORC1 activation in macrophages could sup-
press autophagy, as shown in other cells. However, our
in vitro and in vivo experiments generated the opposite
results and TSC1 deficient macrophages had higher basal
levels of LC3B expression compared to wild type controls.
Our data are similar those derived from experiments using
Tsc1/Tsc2-deficient neurons which were shown to have in-
creased autolysosome accumulation and autophagic flux
despite mTORC1-dependent regulation of ULK1 [33].
Both in the Tsc2-knockdown neurons and in the brains of
Tsc1 conditional mouse models, AMPK activation is the
dominant regulator of autophagy. However, unlike in the
TSC1 KO macrophages, the baseline number of autopha-
gosomes in TSC1/2 deficient neurons was unchanged
despite ULK1 (S757) inhibition, and the accumulation
of autolysomes was rapamycin-insensitve. In contrast to
TSC1/2 KO macrophages and neurons, it was previ-
ously reported that Tsc1/2-deficient mouse embryonic
Fig. 5 Infection of TSC1f/f LysM-Cre+ mice with M. tuberculosis resulted
in lower mycobacterial counts at the time of the arrival of adaptive
immune cells. Both TSC1f/f LysM-Cre+ and LysM-Cre- mice were
aerogenously infected with M. tuberculosis H37Rv with 200-300 bacilli
per lung. Bacterial burdens were measured by CFUs in the lungs (a) at
1, 2, 3, and 5 weeks post-aerosol infection and in the spleens (b) at 3
and 5 weeks post-aerosol infection (n = 4 per time point). c Cytokine
secretion from lung homogenates was determined by Luminex at
3 weeks post-aerosol infection. The data were shown as mean ± SD is
shown (n = 4). d Flow cytometry analysis of MHCII expression in TSC1
WT and KO macrophages at 3 weeks after M. tuberculosis infection is
shown. MFI ± SD is shown (n = 4). MFI =mean fluorescence intensity.
*, p < 0.05
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fibroblasts (MEFs) have reduced autophagy via mTORC1-
dependent phosporylation of ULK1 at S757 [20]. Similarly,
sustained activation of mTORC1 in skeletal muscle in-
hibits constitutive and starvation-induced autophagy and
causes a severe, late-onset myopathy [26]. Furthermore,
due to constitutive mTOR activation, the resulting impair-
ment of autophagy sensitizes TSC2-null cells to cell death
under stress [50]. When starved, TSC1-deficient T cells
show a comparable level of autophagy compared to wild
type T cells, indicating that the increased mTORC1 activ-
ity does not inhibit autophagy in T cells [51]. Such varia-
tions in mTORC1 dependent autophagy regulation could
be attributed to the different cells examined.
In order to demonstrate the active autophagic flux in
TSC1 KO macrophages, we also measured p62 levels as
an important indicator of autophagy-mediated degrad-
ation of cellular contents. p62 is rapidly degraded during
autophagy and analysis of its intracellular level by West-
ern blotting is used routinely to measure the autophagic
flux in response to pro-autophagic stimuli [8]. However,
in our study, p62 protein levels were higher in TSC1 KO
BMMϕ than TSC1 WT BMMϕ and p62 accumulation
was sensitive to rapamycin (Figs. 2a and 3b). We believe
that that the concomitant elevation of p62 and LC3B-II
in TSC1-KO macrophages results from the inability of
turnover to keep pace with increased autophagosome for-
mation, rather than reduction in autophagosome turnover.
When TSC1/TSC2 are disrupted, mTORC1 is consistently
activated to phosphorylate several downstream regulators
for protein synthesis, lipid synthesis, or glycolytic metabol-
ism, leading to energetic stress. These energetic stresses
then activate AMPK, which is a key energy sensor and
regulates cellular metabolism to maintain energy homeo-
stasis [52]. Activated AMPK inhibits mTORC1 through
phosphorylation of TSC2 and Raptor and at the same time
phosphorylates Ulk1 on Ser555 and then initiates autoph-
agy [20, 53]. Thus, in TSC1-KO macrophages, autophagic
machinery is overwhelmed with many autophagosomes
accumulated by AMPK-dependent autophagy activation
due to energetic stress signal. Upon treatment of com-
pound C (Fig. 4d), rapamycin (Fig. 4e), or amino acid
(Fig. 4f), the mTORC1 will be inhibited and cellular stress
will be reduced, which results in lower level of autophagy
activation. Similar results were also observed in TSC1/2
KO MEFs and neurons [33], which have p62 accumulation
that was mTORC1 dependent.
Our data also showed that TSC1f/f LysM-Cre+ mice have
less or similar bacterial burdens in lungs and spleens of
mice aerosol infected with M. tuberculosis H37Rv com-
pared to wild type mice (Fig. 5). In contrast, mice with au-
tophagy defects (ATG5 KO) showed increased bacterial
burden and inflammation in lungs [54]. Thus, consistent
with the enhanced autophagy phenotype shown in TSC1
deficient BMMϕ, our in vivo studies indicated the increased
autophagy induction, not inhibition, in TSC1 KO mice,
which was also supported by a similar level of inflammatory
cytokines and enhanced MHCII level in TSC1 KO mice.
These data implicate the use of novel autophagy inducers
as a therapeutic strategy for TB, especially for drug resistant
TB. However, direct in vivo studies with autophagic protein
(atg) deficiency in TSC KO macrophages will confirm the
result that M. tuberculosis containment and increased
MHCII levels in TSC1 KO mice are the consequence of
increased autophagy.
In summary, our data indicate that constitutively acti-
vated mTORC1 in TSC1 deficient macrophages increases
autophagy through AMPK-dependent regulation of ULK1,
likely to balance energy homeostasis. These findings high-
light the complex regulatory network that modulates
energy metabolism in cells. The fact that mTORC1 de-
regulation is linked to several human diseases, such as
type 2 diabetes, cancer, obesity and neurodegeneration,
highlights the importance of this signaling pathway in the
maintenance of cellular homeostasis [55]. Our findings are
thus relevant to the study of these diseases and may pro-
vide novel insight for the treatment of many human
diseases.
Conclusions
Metabolic homeostasis is orchestrated by mTORC1
through the promotion of biosynthetic pathways and the
repression of catabolic autophagy in response to energy
and amino acid sufficiency. Collectively, the regulation of
these processes is strictly determined by energy and amino
acid sensing pathways within the cell [31, 49]. However,
how constitutive mTORC1 activation affects autophagy is
still controversial. In contrast to the previous studies that
the TSC1-TSC2 complex is a critical negative regulator of
mTORC1 and that TSC1/2 deficient cells have reduced
autophagy via mTORC1-dependent inhibition and phos-
phorylation of ULK1 at S757, we observed that TSC1 defi-
cient macrophages had higher basal and infection induced
autophagy compared to wild type controls. This autoph-
agy dysfunction was mediated through AMPK-dependent
phophorylation of ULK1 at Ser555 concomitant with
mTORC1 inhibition of ULK1 at Ser757. In fact, our re-
sults demonstrate that TSC1 KO macrophages have in-
creased AMP levels suggesting energetic stress. These
results collectively suggest that AMPK activation in
TSC1 KO macrophages is a positive feedback mechan-
ism on autophagy to prevent long-term cellular stress
and maintain cellular homeostasis.
Methods
Mice and reagents
TSC1f/f-ERCre+ mice were previously reported [27, 56].
LysM-Cre+ mice were purchased from Jackson Laboratory.
M. bovis (Bacillus Calmette-Guérin or BCG) was obtained
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from the laboratory of Dr. William Jacobs (Albert Einstein
College of Medicine). Virulent M. tuberculosis H37Rv
(ATCC, 25618D-2) was purchased from ATCC. Rapa-
mycin was obtained from Enzo Life Science (Enzo Life
Science, A275). Bafilomycin A1 (B1793), 3-methyladenine
(3-MA, M9281), and wortmannin (W1628) were pur-
chased from Sigma-Aldrich. Compound C (Millipore,
171,260) was obtained from Millipore (Billerica, MA).
M. tuberculosis H37Rv in vivo infection and CFU
determination
TSC1fl/fl LysM-Cre+ and TSC1fl/fl LysM-Cre- mice were
infected with H37Rv via aerosol infection (200-300 CFUs)
as previously described [57]. The retained dose was deter-
mined by lung necropsy in four mice sacrificed 24 h after
exposure. At specified time points, lungs and spleens re-
moved from the mice were placed in a WhirlPak bag con-
taining 4.5 mL of PBS and homogenized by manually
rolling a pipette on the bag. Defined volumes of the neat
homogenate and serial dilutions were plated on 7H10 agar
plates. The plates were incubated for 4 weeks at 37 °C.
The upper limit and lower limit for colony counting was
300 and 30 colonies per plate, respectively. The total CFU
for each organ was calculated by multiplying CFU counts
by their respective dilution factors.
Bone marrow derived macrophage (BMMϕ) development
and mycobacterial infection
Bone marrow cells from femurs and tibias were flushed
and plated into petri dishes containing RPMI 10 (RPMI
1640 medium supplemented with 10 % FBS, 100 U/ml
penicillin, 1000 U/ml streptomycin, and 20 mM L-glu-
tamine) containing 15 % L929 cell conditioned medium.
After 2–3 days of culture at 37 °C in a CO2 incubator,
non-adherent cells were transferred to new plates with
fresh medium for an additional 3–5 days before they
were used for experiments. To remove TSC1 protein in
BMMϕ in vitro, 4-Hydroxytamoxifen (Sigma-Aldrich,
H7904) at 2.5 mM was added into L929 conditioned cul-
ture medium for 2–3 days before use. For the resident
peritoneal macrophage preparation, macrophages were
washed from the peritoneal cavity with 5 ml of 1x PBS.
After centrifugation at 1500 rpm for 5 min, the cell pel-
lets were resuspended in complete medium (RPMI1640
containing 10 % FBS and antibiotics) and plated in a 12-
well plate. After 2–3 h, non-adherent cells were removed
and freshly prepared complete medium was added with
the indicated stimuli. For mycobacterial infection within
3 h, cells were washed twice with 1x PBS after infection
and then harvested for indicated analysis. For mycobac-
terial infection beyond 3 h, cells were washed twice
with PBS 3 h after infection, and then grown in fresh
complete medium supplemented with 50 μg/ml of gen-
tamycin for indicated periods.
Immunofluorescence microscopy
TSC1 WT and KO BMMϕ were grown on chamber slides
(BD Discovery Labware, 154534) in 10 % FBS RPMI 1640
for 24 h at 37 °C. The cells were treated with or without
rapamycin at 20 ng/ml overnight. The cells were washed
with PBS twice, and then were fixed in 4 % paraformalde-
hyde/PBS for 10 min, permeabilized with 0.2 % Triton X-
100/PBS for 10 min, and pre-blocked in 5 % BSA/PBS
overnight. The slides were then incubated with anti-rabbit
LC3B antibody (Cell Signaling Technology, 2775) that was
diluted at 1/100 in blocking solution for 2 h, washed three
times with PBS, and incubated with Alexa fluor 488-
conjugated anti-rabbit IgG Ab (Invitrogen, A11034). One
hour after additional washes, the slides were mounted
with DAPI containing anti-fade solution (Vector Labora-
tories, INC., H-1200). Images were taken on a Nikon TE
2000 immunofluorescent microscope and analyzed with
NIS Elements software (1,000x magnification). Autophagic
puncta were randomly counted for 20 cells in each group
and averaged.
ELISA/Luminex
BMMϕ (3 × 105) cells were plated into each well of 24 well-
plates and allowed to adhere overnight (Becton Dickinson
Labware, 3574). Both TSC1 WT and KO BMMϕ were in-
fected with BCG or M. tuberculosis H37Rv at an MOI of
10 for indicated periods. The culture supernatants were
harvested to detect IL-1β cytokine levels and were de-
termined by using a commercial ELISA kit (Biolegend,
432606) according to the manufacturer’s instructions.
These cells were then harvested for total RNA isolation.
For Luminex assay, the Mouse Cytokine/Chemokine
Magnetic Bead Panel kit was purchased from EMD
Millipore Corporation (Billerica, MA). The procedure
followed the manufacturer’s instructions using the Bio-
Plex 200 System (Bio-rad).
qRT-PCR
Total RNA was prepared by using TRIzol® reagent
(Invitrogen, 15596-018). Reverse transcription was per-
formed using iScript Reverse Transcriptase (Bio-Rad,
170-8840). SYBR green real-time PCR was conducted
using iQ™ Supermix (Bio-Rad, 170-8880). All reagents
were used according to the manufacturer protocol.
mRNA expression level is defined as fold change over
control (arbitrarily as 1). The primer pairs were used as
follows: β-Actin: forward 5’ TGTCCACCTTCCAGCA
GATGT 3’ and reverse 5’ AGCTCAGTAACAGTCCGCC
TAGA 3’; TNFα: Forward 5’CCCCAAAGGGATGAG
AAGTT and Reverse 5’ CACTTGGTGGTTTGCTACGA;
IL-1α: Forward 5’CGTCAGGCAGAAGTTTGTCA and
Reverse 5’ TTAGAGTCGTCTCCTCCCGA; IL-1β: For-
ward 5’CTCATCTGGGATCCTCTCCA and reverse 5’
TGTCAAAAGGTGGCATTTCA.
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Western blot
TSC1 WT and KO BMMϕ (3 × 105 cells/well) were seeded
into 12-well plates in RPMI complete medium without
L929 conditional medium overnight. Cells were infected
with the indicated bacteria at an MOI of 10. After 3 h post
infection, cells were washed once in PBS followed by
addition of complete medium supplemented with 50 ug/ml
gentamycin (Invitrogen, 15750-060). Cells were cultured
until the indicated time points. Cells were washed once in
PBS and lysed in 1 % Triton-100 lysis buffer (1 % Triton-
100, 150 mM NaCl, 50 mM Tris, pH 7.4, 1 mM EDTA)
with protease inhibitor tablet and phosphatase inhibitor
cocktails (Sigma, S8820). Protein concentrations were de-
termined using a Bio-Rad Protein Assay at OD600 nm
(Bio-Rad, 500-0006). Equivalent amounts of protein for
each sample were subjected to SDS-polyacrylamide gel
electrophoresis and transferred onto methanol equilibrated
PVDF membrane (BIO-RAD Laboratories, 162-0177).
After blocking with 5 % nonfat dry milk/PBS, the mem-
branes were incubated with a primary antibody overnight
at 4 °C, and washed with PBST (100 mM Tris, pH 7.5,
NaCl 0.9 %, Tween 0.1 %). Secondary antibody was added
for 45 min at room temperature, and the membrane was
washed with PBST three times. Protein bands were visual-
ized by ECL (Perkin Elmer Life Sciences, NE104001EA).
The following antibodies were used for immunoblotting:
Rabbit anti-LC3B (2775), p-S6 (Ser240/244) (4857), p-
ULK1 (Ser757) (6888) or (Ser555) (5869), p-AMPKα
(T172) (2535), Beclin1 (3738), ATG5 (2630), p62 (5114)
from Cell Signaling Technology, and mouse anti-β-
actin (Sigma-Aldrich, A5441). Films were scanned and
ImageJ software was used to quantify band intensities.
As described in Individual figures, band intensity of
LC3B-II was related to the level of β-actin.
Flow cytometry
Cells were stained with the indicated antibodies in FACS
buffer (PBS containing 2 % FBS) at 4 °C for 30 min. Cells
were pelleted and washed once with FACS buffer and re-
suspended in 4 % paraformaldehyde at least 2 h before
analysis. Fluorescently conjugated antibodies used were
APC-anti-F4/80 (123116), PE/Cy5-anti-Gr1 (108410), PE/
Cy7-anti-CD11b (101216), and PE-anti-CD45 (103106)
from Biolegend. Data were collected using a BD FACS
canto or LSRII and analyzed with FlowJo (Tree Star).
AMP quantitation
Approximately 30 million BMMϕ cells from TSC1f/f-
ERCre+ or TSC1f/f-ERCre− mouse were plated into one
10 cm petri dish in 15 % L929 conditional medium in tripli-
cate. After 24 h, cells were washed twice with the warmed
1x PBS, scraped in the same PBS, and spun at 2000 rpm for
5 min at 4 °C. The cell pellets were stored at -80 °C for fu-
ture use. The LC-MS/MS method was described previously
[58]. The sample processing was performed in the DMPI
Metabolomics Laboratory, Duke University.
ShRNA transduction
ShRaptor and ShLuc control were purchased from
Addgene (21339). 293FT cells were transfected using the
Fugene 6 Transfection Reagent (Promega Corporation,
E269A). The viral supernatants were collected 48 h after
transfection and frozen at -80 °C for future transduction.
For infection, 2 × 105 cells in 1 mL of RPMI 10 were mixed
with 0.5 mL of viral supernatant in a 6-well plate, along
with 5ug/mL of polybrene (EMD Millipore, TR-1003-G).
Cells were centrifuged at 2500 g for 1.5 h at room
temperature. Fresh complete medium was added to the
cells 7 h after infection. After 24 h of infection, cells
were treated with puromycin (Sigma, P9620) at 2 μg/ml
for 3-4 days.
Statistical analysis
P values were calculated using the student’s t-test or
ANOVA analysis. P values of less than 0.05 or 0.01 were
considered significant or very significant, respectively.
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